Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | APGN | Common Stock | Award | $0 | +75K | +338.8% | $0.00 | 97.1K | May 23, 2023 | Direct | F1, F2 |
transaction | APGN | Common Stock | Tax liability | -$4.89K | -12.2K | -12.59% | $0.40 | 84.9K | May 23, 2023 | Direct | F3 |
Id | Content |
---|---|
F1 | The reported shares are represented by restricted stock units, or RSUs. Upon signing of the merger agreement between the Issuer and Pyxis Oncology, Inc. dated May 23, 2023, 30,000 RSUs vested. The remaining 45,000 RSUs vest on the earlier of (i) the closing of the merger or (ii) September 30, 2023. |
F2 | Includes 8,500 shares acquired on May 15, 2023 pursuant to the Issuer's 2022 Employee Stock Purchase Plan. |
F3 | The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of RSUs. |